Most cancer drugs work by blocking a protein. Vepdegestrant, approved by the FDA on 1 May 2026 under the brand name Veppanu, removes it. That is the technical reality behind the first approval of a PROTAC, short for PROteolysis TArgeting Chimera, a class of heterobifunctional protein degraders that Arvinas has pursued since 2013.
The agency cleared the pill for adults with ER-positive, HER2-negative breast cancer that is advanced or metastatic, carries a mutation in the ESR1 gene, and has advanced after at least one earlier round of endocrine treatment. An FDA-authorized test has to detect the mutation, and Guardant Health’s Guardant360 CDx was approved alongside it as the companion diagnostic. Arvinas discovered the drug and developed it jointly with Pfizer. The decision landed ahead of the June 5 date the FDA had set for its ruling.
Why ESR1 matters
The target population is narrow, and for good reason. Endocrine therapy is a cornerstone of treatment for ER-positive, HER2-negative disease, but according to Arvinas, as many as 40-50% of patients given endocrine therapy plus a CDK4/6 inhibitor end up with ESR1 mutations. Those mutations drive resistance, and the patients often progress quickly with few options after first-line treatment. “There have been minimal second-line treatment options once standard therapies are no longer effective,” said Erika Hamilton of the Sarah Cannon Research Institute, a principal investigator on the pivotal trial.
What the trial showed
Approval rested on VERITAC-2, a global, randomized, open-label Phase 3 study that set vepdegestrant against fulvestrant. The trial enrolled 624 patients, 270 of whom had an ESR1 mutation. In that subgroup vepdegestrant lowered the risk of progression or death by 43%. Median progression-free survival was 5 months on vepdegestrant against 2.1 months on fulvestrant. Overall survival data were immature, with deaths in 16% of that group when the progression analysis was run.
Modest numbers, as ever, and the detail that matters: fulvestrant is given as an intramuscular injection, while Veppanu is an oral treatment. Most adverse events were low grade, Grade 1 or 2. The most frequent reactions included lower white blood cell counts, raised AST, muscle and bone pain, and fatigue.
What comes next
Randy Teel, Arvinas’ chief executive, called the approval a transformative moment, the company’s first approved medicine and “the first-ever approved PROTAC therapy.” He said the companies were on track to announce a third party to bring the drug to patients. Arvinas and Pfizer plan to pick a partner with the commercial expertise to market it.
Sources
- Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer – BioSpace
- Arvinas and Pfizer Report the US FDA Approval of Veppanu (Vepdegestrant) for ESR1-Mutated Breast Cancer – PharmaShots
- Pfizer, Arvinas Win FDA Nod for PROTAC Therapy Cutting Progression Risk 43% – PFE News | Rallies
Sources
- Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer
- Google News – FDA approval of Vepdegestrant – Overview
